Please login to the form below

Not currently logged in
Email:
Password:

Pfizer halts osteoarthritis trial

Pfizer has suspended its global phase III clinical trials programme testing the investigational painkiller tanezumab in osteoarthritis

Based on a request from the US Food and Drug Administration (FDA), Pfizer has suspended its global phase III clinical trials programme testing the investigational painkiller tanezumab in osteoarthritis. The FDA's request was based on a small number of reports of osteoarthritis worsening in subjects taking the drug, sometimes even leading to the need for joint replacement.

The adverse event has not been observed in tanezumab patients in clinical programmes for other indications, the company noted. However, at the FDA's request, Pfizer will meet with the agency this week "to present its assessment of the potential implications of the adverse events in the osteoarthritis programme for the other tanezumab clinical programmes."

The programmes include ongoing studies in patients with cancer pain, interstitial cystitis, chronic low back pain and diabetic peripheral neuropathy.

The clinical hold, which is effective immediately, suspends the recruitment of new osteoarthritis patients and the dosing of existing osteoarthritis subjects, as well as dosing of patients with osteoarthritis in other studies.

Tanezumab is a humanised monoclonal antibody directed against nerve growth factor. It was acquired by Pfizer when the company bought the biotech firm Rinat in 2006.

The announcement of the suspension of the tanezumab programme comes directly on the heels of other negative safety-related news for Pfizer. Earlier this week, the company said it would withdraw its cancer drug Mylotarg (gemtuzumab ozogamicin) from the US at the request of the FDA after postmarketing data found that the drug, which was approved based on surrogate endpoints under the FDA's accelerated approval programme, was not as safe or effective as it appeared to be in pre-marketing studies.

24th June 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health

Cello Health’s mission is to help our clients unlock the potential that exists with their assets, brands and organisations in...

Latest intelligence

segmentation_pie_thumb.jpg
If you’re not thinking segmentation, you’re not thinking
Having a background in market research I’ve been lucky to work on a number of customer segmentations in my time but working in creative communications it is still too rare...
Improving Outcomes in the Treatment of Opioid Dependence Highlights Report
The 16th annual ‘Improving Outcomes in the Treatment of Opioid Dependence’ (IOTOD)conference took place at the Hilton Madrid Airport hotel on 15–16 May 2018....
Londonvelophobia (fear of cycling in London) – debunked
...

Infographics